Repurposing GLP1 agonists for neurodegenerative diseases
- PMID: 32854860
- DOI: 10.1016/bs.irn.2020.02.007
Repurposing GLP1 agonists for neurodegenerative diseases
Abstract
There is a large unmet medical need to find disease modifying therapies against neurodegenerative diseases. This review summarizes data indicating that insulin resistance occurs in neurodegeneration and strategies to normalize insulin sensitivity in neurons may provide neuroprotective actions. In particular, recent preclinical and clinical studies in Parkinson's disease and Alzheimer's disease have indicated that glucagon-like peptide 1 (GLP1) agonism and dipeptidyl peptidase-4 inhibition may exert neuroprotection. Mechanistic insights from these studies and future directions for drug development against neurodegeneration based on GLP1 agonism are discussed.
Keywords: Alzheimer's disease; GLP1; Insulin; Neurodegenerative diseases; Parkinson's disease.
© 2020 Elsevier Inc. All rights reserved.
Conflict of interest statement
Conflicts of interest The authors have no conflicts of interest to declare.
Similar articles
-
Parkinson's Disease, Diabetes and Cognitive Impairment.Recent Pat Endocr Metab Immune Drug Discov. 2016;10(1):11-21. doi: 10.2174/1872214810999160628105549. Recent Pat Endocr Metab Immune Drug Discov. 2016. PMID: 27396477 Review.
-
Repurposing antidiabetic drugs for Alzheimer's disease: A review of preclinical and clinical evidence and overcoming challenges.Life Sci. 2024 Oct 15;355:123001. doi: 10.1016/j.lfs.2024.123001. Epub 2024 Aug 21. Life Sci. 2024. PMID: 39173996 Review.
-
Evaluation of neuroprotective effect of glucagon-like peptide 1 analogs using neuroimaging.Alzheimers Dement. 2014 Feb;10(1 Suppl):S55-61. doi: 10.1016/j.jalz.2013.12.012. Alzheimers Dement. 2014. PMID: 24529526 Review.
-
Repositioning of dipeptidyl peptidase-4 inhibitors and glucagon like peptide-1 agonists as potential neuroprotective agents.Neural Regen Res. 2019 May;14(5):745-748. doi: 10.4103/1673-5374.249217. Neural Regen Res. 2019. PMID: 30688255 Free PMC article. Review.
-
Exendin-4: A potential therapeutic strategy for Alzheimer's disease and Parkinson's disease.Chem Biol Drug Des. 2024 Jan;103(1):e14426. doi: 10.1111/cbdd.14426. Chem Biol Drug Des. 2024. PMID: 38230775 Review.
Cited by
-
Trends on Novel Targets and Nanotechnology-Based Drug Delivery System in the Treatment of Parkinson's disease: Recent Advancement in Drug Development.Curr Drug Targets. 2024;25(15):987-1011. doi: 10.2174/0113894501312703240826070530. Curr Drug Targets. 2024. PMID: 39313872 Review.
-
A Comprehensive Approach to Parkinson's Disease: Addressing Its Molecular, Clinical, and Therapeutic Aspects.Int J Mol Sci. 2024 Jun 29;25(13):7183. doi: 10.3390/ijms25137183. Int J Mol Sci. 2024. PMID: 39000288 Free PMC article. Review.
-
[The role of antidiabetic drugs in the treatment of Alzheimer's disease: systematic review].Probl Endokrinol (Mosk). 2023 Nov 11;69(5):73-83. doi: 10.14341/probl13183. Probl Endokrinol (Mosk). 2023. PMID: 37968954 Free PMC article. Russian.
-
A Study on Methodologies of Drug Repositioning Using Biomedical Big Data: A Focus on Diabetes Mellitus.Endocrinol Metab (Seoul). 2022 Apr;37(2):195-207. doi: 10.3803/EnM.2022.1404. Epub 2022 Apr 13. Endocrinol Metab (Seoul). 2022. PMID: 35413782 Free PMC article.
-
Divergent Effect of Central Incretin Receptors Inhibition in a Rat Model of Sporadic Alzheimer's Disease.Int J Mol Sci. 2022 Jan 4;23(1):548. doi: 10.3390/ijms23010548. Int J Mol Sci. 2022. PMID: 35008973 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
